Work

Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab

Year: 2020

Type: review

Abstract: Renal cell carcinoma (RCC) is among the 10 most common cancers in the USA. One-third of the patients diagnosed with this cancer present with locally advanced or metastatic disease. In the past, advanced disease conferred poor survival outcomes; however, the treatment paradigm for RCC has been revolutionized twice since 2005. The initial wave of revolution came with the emergence of vascular endothelial growth factor (VEGF) inhibitors and a second wave arose more recently with the emergence and unprecedented success of checkpoint inhibitors in RCC. A third wave combining these two strategies is well underway and likely represents the new paradigm to improve survival outcomes for afflicted patients. In this review, we discuss the current treatment landscape for patients with advanced RCC, focusing on approved VEGF and checkpoint inhibitors in the first-line setting as well as highlighting landmark combination clinical trials.

Source: OncoTargets and Therapy

DOI: 10.2147/ott.s215173

Authors: Abhay Singh, Inderpreet Singh, Namrata Singh, Igor Puzanov

Institutions: Roswell Park Comprehensive Cancer Center, University of Colorado Anschutz, Punjab Institute of Medical Sciences

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,836